South Korea
· Delayed Price · Currency is KRW ABL Bio Statistics
Total Valuation
ABL Bio has a market cap or net worth of KRW 1.27 trillion. The enterprise value is 1.17 trillion.
| Market Cap | 1.27T |
| Enterprise Value | 1.17T |
Important Dates
The next estimated earnings date is Friday, March 14, 2025.
| Earnings Date | Mar 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ABL Bio has 48.28 million shares outstanding. The number of shares has increased by 0.28% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 48.28M |
| Shares Change (YoY) | +0.28% |
| Shares Change (QoQ) | +0.20% |
| Owned by Insiders (%) | 30.40% |
| Owned by Institutions (%) | 20.53% |
| Float | 33.60M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 39.16 |
| PB Ratio | 7.13 |
| P/TBV Ratio | 7.26 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -23.78 |
| EV / Sales | 36.09 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -14.33 |
Financial Position
The company has a current ratio of 7.80, with a Debt / Equity ratio of 0.24.
| Current Ratio | 7.80 |
| Quick Ratio | 7.71 |
| Debt / Equity | 0.24 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.54 |
| Interest Coverage | -240.59 |
Financial Efficiency
Return on equity (ROE) is -36.81% and return on invested capital (ROIC) is -17.93%.
| Return on Equity (ROE) | -36.81% |
| Return on Assets (ROA) | -15.04% |
| Return on Capital (ROIC) | -17.93% |
| Revenue Per Employee | 316.87M |
| Profits Per Employee | -480.80M |
| Employee Count | 102 |
| Asset Turnover | 0.15 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +25.71% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +25.71% |
| 50-Day Moving Average | 33,183.00 |
| 200-Day Moving Average | 28,471.00 |
| Relative Strength Index (RSI) | 37.14 |
| Average Volume (20 Days) | 841,226 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, ABL Bio had revenue of KRW 32.32 billion and -49.04 billion in losses. Loss per share was -1,022.84.
| Revenue | 32.32B |
| Gross Profit | 32.26B |
| Operating Income | -50.44B |
| Pretax Income | -49.04B |
| Net Income | -49.04B |
| EBITDA | -48.00B |
| EBIT | -50.44B |
| Loss Per Share | -1,022.84 |
Balance Sheet
The company has 155.11 billion in cash and 43.93 billion in debt, giving a net cash position of 111.18 billion or 2,302.77 per share.
| Cash & Cash Equivalents | 155.11B |
| Total Debt | 43.93B |
| Net Cash | 111.18B |
| Net Cash Per Share | 2,302.77 |
| Equity (Book Value) | 180.79B |
| Book Value Per Share | 3,702.52 |
| Working Capital | 136.82B |
Cash Flow
In the last 12 months, operating cash flow was -71.19 billion and capital expenditures -10.21 billion, giving a free cash flow of -81.40 billion.
| Operating Cash Flow | -71.19B |
| Capital Expenditures | -10.21B |
| Free Cash Flow | -81.40B |
| FCF Per Share | -1,685.93 |
Margins
Gross margin is 99.81%, with operating and profit margins of -156.07% and -151.73%.
| Gross Margin | 99.81% |
| Operating Margin | -156.07% |
| Pretax Margin | -151.73% |
| Profit Margin | -151.73% |
| EBITDA Margin | -148.51% |
| EBIT Margin | -156.07% |
| FCF Margin | n/a |
Dividends & Yields
ABL Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.28% |
| Shareholder Yield | -0.28% |
| Earnings Yield | -3.87% |
| FCF Yield | -6.39% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ABL Bio has an Altman Z-Score of 8.8.
| Altman Z-Score | 8.8 |
| Piotroski F-Score | n/a |